These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 19799953

  • 1. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
    Cirillo G, Maggio N, Bianco MR, Vollono C, Sellitti S, Papa M.
    Neurochem Int; 2010 Jan; 56(1):152-60. PubMed ID: 19799953
    [Abstract] [Full Text] [Related]

  • 2. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J.
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [Abstract] [Full Text] [Related]

  • 3. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease.
    Pandey M, Varghese M, Sindhu KM, Sreetama S, Navneet AK, Mohanakumar KP, Usha R.
    J Neurochem; 2008 Jan; 104(2):420-34. PubMed ID: 17953654
    [Abstract] [Full Text] [Related]

  • 4. Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes.
    Duran-Vilaregut J, Del Valle J, Manich G, Junyent F, Camins A, Pallàs M, Pelegrí C, Vilaplana J.
    Neurochem Int; 2010 Feb; 56(3):443-50. PubMed ID: 19969037
    [Abstract] [Full Text] [Related]

  • 5. Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats.
    Deshpande SB, Hida H, Takei-Io N, Masuda T, Baba H, Nishino H.
    Brain Res; 2006 Sep 07; 1108(1):205-15. PubMed ID: 16857175
    [Abstract] [Full Text] [Related]

  • 6. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
    Dalbem A, Silveira CV, Pedroso MF, Breda RV, Werne Baes CV, Bartmann AP, da Costa JC.
    Brain Res; 2005 Jun 21; 1047(2):148-58. PubMed ID: 15901483
    [Abstract] [Full Text] [Related]

  • 7. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
    Pandey M, Borah A, Varghese M, Barman PK, Mohanakumar KP, Usha R.
    Neurochem Int; 2009 Nov 21; 55(6):431-7. PubMed ID: 19410615
    [Abstract] [Full Text] [Related]

  • 8. Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.
    Chang KL, New LS, Mal M, Goh CW, Aw CC, Browne ER, Chan EC.
    J Proteome Res; 2011 Apr 01; 10(4):2079-87. PubMed ID: 21355552
    [Abstract] [Full Text] [Related]

  • 9. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
    Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC.
    Exp Neurol; 2001 Oct 01; 171(2):351-60. PubMed ID: 11573988
    [Abstract] [Full Text] [Related]

  • 10. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
    Dhir A, Akula KK, Kulkarni SK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr 01; 32(3):835-43. PubMed ID: 18234412
    [Abstract] [Full Text] [Related]

  • 11. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.
    Escartin C, Boyer F, Bemelmans AP, Hantraye P, Brouillet E.
    Neurosci Lett; 2007 Oct 02; 425(3):167-72. PubMed ID: 17868993
    [Abstract] [Full Text] [Related]

  • 12. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
    Silva-Adaya D, Pérez-De La Cruz V, Herrera-Mundo MN, Mendoza-Macedo K, Villeda-Hernández J, Binienda Z, Ali SF, Santamaría A.
    J Neurochem; 2008 May 02; 105(3):677-89. PubMed ID: 18194214
    [Abstract] [Full Text] [Related]

  • 13. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
    Rossignol J, Boyer C, Lévèque X, Fink KD, Thinard R, Blanchard F, Dunbar GL, Lescaudron L.
    Behav Brain Res; 2011 Mar 01; 217(2):369-78. PubMed ID: 21070819
    [Abstract] [Full Text] [Related]

  • 14. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid.
    El Massioui N, Ouary S, Chéruel F, Hantraye P, Brouillet E.
    Exp Neurol; 2001 Nov 01; 172(1):172-81. PubMed ID: 11681849
    [Abstract] [Full Text] [Related]

  • 15. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
    Tadros MG, Khalifa AE, Abdel-Naim AB, Arafa HM.
    Pharmacol Biochem Behav; 2005 Nov 01; 82(3):574-82. PubMed ID: 16337998
    [Abstract] [Full Text] [Related]

  • 16. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC, Hantraye P, Dolan R, Palfi S, Maziére M, Brouillet E.
    Neuroscience; 1997 Jul 01; 79(1):45-56. PubMed ID: 9178864
    [Abstract] [Full Text] [Related]

  • 17. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
    Kumar P, Kumar A.
    Behav Brain Res; 2010 Jan 05; 206(1):38-46. PubMed ID: 19716383
    [Abstract] [Full Text] [Related]

  • 18. Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes.
    Singh S, Misiak M, Beyer C, Arnold S.
    Glia; 2009 Nov 01; 57(14):1480-91. PubMed ID: 19306371
    [Abstract] [Full Text] [Related]

  • 19. N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease.
    Sandhir R, Sood A, Mehrotra A, Kamboj SS.
    Neurodegener Dis; 2012 Nov 01; 9(3):145-57. PubMed ID: 22327485
    [Abstract] [Full Text] [Related]

  • 20. Mitochondrial cofactors in experimental Huntington's disease: behavioral, biochemical and histological evaluation.
    Mehrotra A, Sandhir R.
    Behav Brain Res; 2014 Mar 15; 261():345-55. PubMed ID: 24393741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.